In metastatic cancer, ZNF217 amplification ranks among the most frequent genetic alterations and its overexpression was reported to be associated with poor outcome, suggesting an oncogenic function [21, 40, 41]. Here, ZNF217 is linked to metastatic malignant neoplasm.